Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | SMO F460L |
Therapy | Vismodegib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
SMO F460L | Advanced Solid Tumor | resistant | Vismodegib | Preclinical | Actionable | In a preclinical study, a transformed cell line expressing SMO F460L demonstrated resistance to Erivedge (vismodegib) as compared to wild-type (PMID: 25759020). | 25759020 |
PubMed Id | Reference Title | Details |
---|---|---|
(25759020) | Smoothened variants explain the majority of drug resistance in basal cell carcinoma. | Full reference... |